Sugi Predict

Sugi Predict / Compounds / SCHEMBL1774277

SCHEMBL1774277

SCHEMBL1774277

O=c1c(O)c(CNCc2ccccc2)ccn1Cc1ccc(Cl)cc1

nearest known ligand 1.00 ✓ in ChEMBL — recovers established targets

Predicted protein targets (top 12)

geneUniProtsupporting neighboursconfidence
▸ EGLN1 Q9GZT9 13/20 1.00
▸ VEGFA P15692 12/20 1.00
▸ LMNA P02545 3/20 0.55
▸ HTT P42858 2/20 0.55
▸ ALDH1A1 P00352 3/20 0.52
▸ MEN1 O00255 2/20 0.52
▸ MAPT P10636 2/20 0.52
▸ KMT2A Q03164 2/20 0.52
▸ POLB P06746 2/20 0.46
▸ KDM4E B2RXH2 1/20 0.45
▸ HPGD P15428 1/20 0.44
▸ NPSR1 Q6W5P4 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL272670 0.94 EGLN1 (0.88) EGLN1VEGFALMNAHTTALDH1A1
SCHEMBL12599456 0.89 EGLN1 (0.80) EGLN1VEGFALMNAHTTALDH1A1
SCHEMBL24512412 0.88 EGLN1 (0.78) EGLN1VEGFALMNAHTTALDH1A1
SCHEMBL272385 0.86 EGLN1 (0.76) EGLN1VEGFAHTTALDH1A1KDM4E
SCHEMBL272319 0.86 VEGFA (0.75) EGLN1VEGFALMNAHTTMEN1
SCHEMBL12669231 0.81 EGLN1 (0.72) EGLN1VEGFAHTTKDM4E
SCHEMBL278450 0.80 EGLN1 (0.66) EGLN1VEGFALMNAHTTALDH1A1
SCHEMBL273704 0.78 EGLN1 (1.00) EGLN1VEGFAHTTMEN1MAPT
SCHEMBL272502 0.78 EGLN1 (0.71) EGLN1VEGFAHTTMEN1KMT2A
SCHEMBL16790886 0.78 EGLN1 (0.64) EGLN1VEGFALMNAHTTALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 64 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20220185778-A1 PROLYL HYDROXYLASE INHIBITORS AERPIO THERAPEUTICS INC (US) 2022-06-16 — — US disclosed
US-10562854-B2 Prolyl hydroxylase inhibitors AERPIO THERAPEUTICS, INC. (US) 2020-02-18 — — US disclosed
US-10562854-B2 Prolyl hydroxylase inhibitors AERPIO THERAPEUTICS, INC. (US) 2020-02-18 — — US disclosed
EP-3603644-A1 PROLYL HYDROXYLASE INHIBITORS Aerpio Therapeutics, Inc. (US) 2020-02-05 — — EP disclosed
EP-3603644-A1 PROLYL HYDROXYLASE INHIBITORS Aerpio Therapeutics, Inc. (US) 2020-02-05 — — EP disclosed
EP-2952192-B1 Prolyl hydroxylase inhibitors AERPIO THERAPEUTICS INC (US) 2019-05-15 — — EP disclosed
EP-2952192-B1 Prolyl hydroxylase inhibitors AERPIO THERAPEUTICS INC (US) 2019-05-15 — — EP disclosed
US-20190055198-A1 PROLYL HYDROXYLASE INHIBITORS AERPIO THERAPEUTICS LLC 2019-02-21 — — US disclosed
US-20190055198-A1 PROLYL HYDROXYLASE INHIBITORS AERPIO THERAPEUTICS LLC 2019-02-21 — — US disclosed
US-20170298019-A1 PROLYL HYDROXYLASE INHIBITORS AERPIO THERAPEUTICS LLC 2017-10-19 — — US disclosed
EP-2496236-B1 PROLYL HYDROXYLASE INHIBITORS AERPIO THERAPEUTICS INC (US) 2013-05-01 — — EP disclosed
US-8309537-B2 Compositions and methods for treating colitis AERPIO THERAPEUTICS INC. (US) 2012-11-13 — — US disclosed
US-8309537-B2 Compositions and methods for treating colitis AERPIO THERAPEUTICS INC. (US) 2012-11-13 — — US disclosed
US-20110111058-A1 METHODS FOR INCREASING THE STABILIZATION OF HYPOXIA INDUCIBLE FACTOR-1 ALPHA AERPIO THERAPEUTICS LLC 2011-05-12 — — US disclosed
US-20110112055-A1 COMPOSITIONS AND METHODS FOR TREATING COLITIS AERPIO THERAPEUTICS LLC 2011-05-12 — — US disclosed
US-20110111058-A1 METHODS FOR INCREASING THE STABILIZATION OF HYPOXIA INDUCIBLE FACTOR-1 ALPHA AERPIO THERAPEUTICS LLC 2011-05-12 — — US disclosed
US-20110111058-A1 METHODS FOR INCREASING THE STABILIZATION OF HYPOXIA INDUCIBLE FACTOR-1 ALPHA AERPIO THERAPEUTICS LLC 2011-05-12 — — US disclosed
US-20110112055-A1 COMPOSITIONS AND METHODS FOR TREATING COLITIS AERPIO THERAPEUTICS LLC 2011-05-12 — — US disclosed
US-20110110961-A1 PROLYL HYDROXYLASE INHIBITORS AERPIO THERAPEUTICS LLC 2011-05-12 — — US disclosed
US-20110110961-A1 PROLYL HYDROXYLASE INHIBITORS AERPIO THERAPEUTICS LLC 2011-05-12 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20170298019-A1 PROLYL HYDROXYLASE INHIBITORS HIF1AN, HIF1A, EGLN2 EGLN1 5/4885VEGFA 551/4885LMNA 4204/4885
US-20110112055-A1 COMPOSITIONS AND METHODS FOR TREATING COLITIS ALPI, SI, SLC10A2 EGLN1 2861/4885VEGFA 4546/4885LMNA 3092/4885
US-20190055198-A1 PROLYL HYDROXYLASE INHIBITORS HIF1AN, HIF1A, EGLN2 EGLN1 5/4885VEGFA 551/4885LMNA 4204/4885
US-20220185778-A1 PROLYL HYDROXYLASE INHIBITORS HIF1AN, HIF1A, EGLN2 EGLN1 5/4885VEGFA 551/4885LMNA 4204/4885
US-20110111058-A1 METHODS FOR INCREASING THE STABILIZATION OF HYPOXIA INDUCIBLE FACTOR-1 ALPHA HIF1A, HIF1AN, EGLN3 EGLN1 8/4885VEGFA 20/4885LMNA 1236/4885
US-20110110961-A1 PROLYL HYDROXYLASE INHIBITORS HIF1AN, HIF1A, EGLN2 EGLN1 5/4885VEGFA 551/4885LMNA 4204/4885
US-10562854-B2 Prolyl hydroxylase inhibitors HIF1AN, HIF1A, EGLN2 EGLN1 5/4885VEGFA 551/4885LMNA 4204/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.